Ignored "IF": search terms need at least 3 characters.
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
It is very uncertain whether 2‐hourly repositioning changes pressure injury (stages 1 to 4) Short‐term compared with 4‐hourly repositioning (very low certainty).
It is very uncertain whether 30° 3‐hourly tilt changes pressure injury (stages 1 to 4) Short‐term compared with 90° tilt (very low certainty).
It is very uncertain whether hypertonic saline changes mortality (short‐term) compared with other intracranial pressure‐lowering agents (very low certainty).
It is very uncertain whether azelaic acid changes total number of participants who experienced at least one minor… compared with benzoyl peroxide (very low certainty).
It is very uncertain whether etretinate changes proportion of participants cleared or almost cleared in the short… compared with placebo or no treatment (very low certainty).
It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants cleared or almost cleared in the short… compared with placebo with PUVA therapy (very low certainty).
It is very uncertain whether etretinate changes proportion of participants cleared or almost cleared in the short… compared with PUVA therapy (very low certainty).
Etanercept showed no clear difference in proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).
Ustekinumab showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (low certainty).
Topical vitamin D derivative may leads to higher proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether the intervention changes 1.2 Number of episodes of aggression (CBA)—short‐term (very low certainty).